Phase 3 Clinical Trials With Primary Completion Dates in July 2016
This is a list of Phase 3 trials with primary completion dates in July 2016 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| ANTH | Anthera Pharmaceuticals, Inc. | 2016-07-01 | Phase 3 | NCT01395745 | CHABLIS-SC1: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus |
| ARDM | Aradigm Corporation | 2016-07-01 | Phase 3 | NCT02104245 | Phase 3 Study With Dual Release Ciprofloxacin for Inhalation in Non-CF Bronchiectasis |
| ARDM | Aradigm Corporation | 2016-07-01 | Phase 3 | NCT01515007 | Phase 3 Study With Dual Release Ciprofloxacin for Inhalation in Non-CF Bronchiectasis |
| EVOK | Evoke Pharma, Inc. | 2016-07-01 | Phase 3 | NCT02025751 | Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Men With Diabetic Gastroparesis |
| EVOK | Evoke Pharma, Inc. | 2016-07-01 | Phase 3 | NCT02025725 | Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Women With Diabetic Gastroparesis |
| FGEN | FibroGen, Inc | 2016-07-01 | Phase 3 | NCT02652819 | FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease Not on Dialysis |
| JAZZ | Jazz Pharmaceuticals plc | 2016-07-01 | Phase 3 | NCT00628498 | Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study |
| NVCR | NovoCure Limited | 2016-07-01 | Phase 3 | NCT00916409 | Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM) |
| ONTX | Onconova Therapeutics, Inc. | 2016-07-01 | Phase 3 | NCT01241500 | Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts |
| OPHT | Ophthotech Corporation | 2016-07-01 | Phase 3 | NCT01944839 | A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy |
| OPHT | Ophthotech Corporation | 2016-07-01 | Phase 3 | NCT01940900 | A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy |
| OPHT | Ophthotech Corporation | 2016-07-01 | Phase 3 | NCT01940887 | A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy |
| OTIC | Otonomy, Inc. | 2016-07-01 | Phase 3 | NCT02600559 | Open-Label Study of OTO-201 in Pediatric Subjects With a History of Otitis Media Requiring Tympanostomy Tubes |
| PRAH | PRA Health Sciences, Inc. | 2016-07-01 | Phase 3 | NCT02338960 | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension |
| PTN | Palatin Technologies, Inc. | 2016-07-01 | Phase 3 | NCT02338960 | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension |
| RDHL | Redhill Biopharma Ltd. | 2016-07-01 | Phase 3 | NCT01951326 | Efficacy and Safety of Anti-MAP Therapy in Adult Crohn's Disease |
| RDY | Dr. Reddy's Laboratories Ltd | 2016-07-01 | Phase 3 | NCT02572986 | A Study to Evaluate the Therapeutic Equivalence of Generic Permethrin Cream 5% to Elimite® in the Treatment of Scabies |
| SGYP | Synergy Pharmaceuticals, Inc. | 2016-07-01 | Phase 3 | NCT02493452 | Second Plecanatide Study In Irritable Bowel Syndrome With Constipation (IBS-C) |
| SGYPU | Synergy Pharmaceuticals, Inc. | 2016-07-01 | Phase 3 | NCT02493452 | Second Plecanatide Study In Irritable Bowel Syndrome With Constipation (IBS-C) |
| TENX | Tenax Therapeutics, Inc. | 2016-07-01 | Phase 3 | NCT02025621 | Levosimendan in Patients With Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery On Cardiopulmonary Bypass |
| VRX | Valeant Pharmaceuticals International, Inc. | 2016-07-01 | Phase 3 | NCT02535871 | A Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris |
| VRX | Valeant Pharmaceuticals International, Inc. | 2016-07-01 | Phase 3 | NCT02491060 | A Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris |
| VRX | Valeant Pharmaceuticals International, Inc. | 2016-07-01 | Phase 3 | NCT02462083 | Long-Term Safety of IDP-118 Lotion in the Treatment of Plaque Psoriasis |
| VRX | Valeant Pharmaceuticals International, Inc. | 2016-07-01 | Phase 3 | NCT02515097 | Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis |
| VRX | Valeant Pharmaceuticals International, Inc. | 2016-07-01 | Phase 3 | NCT02514577 | Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis |